Show Summary Details
Page of

Regulatory Issues 

Regulatory Issues
Regulatory Issues

Thomas P. Laughren

and Mark A. Ritter

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 22 January 2022

Chapter 51 reviews U.S. Food and Drug Administration (FDA) initiatives in recent years to stimulate drug research in the pediatric population and the impact of these initiatives on drug development in pediatric psychopharmacology, the substantial regulatory changes that have been implemented that have led to additional clinical trials being conducted in pediatric patients for psychiatric indications. The chapter also considers the assessment of safety, the balancing of science and ethics, the preschool population, and other issues that must be addressed for drug development in this area to progress, and includes a brief overview of drug development and the regulatory process. In some cases, it will be necessary to limit details of the discussion to protect the proprietary rights of individual sponsors who have drug development programs under way in this area.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.